1
Paul J Carter, Leonard G Presta: Immunoglobulin variants. Genentech, Wendy M Lee, October 13, 1998: US05821337 (544 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


2
Paul J Carter, Leonard G Presta: Humanized antibodies and methods for making them. Genentech, Wendy M Lee, April 25, 2000: US06054297 (468 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


3
Paul J Carter, Leonard G Presta: Method for making humanized antibodies. Genentech, Wendy M Lee, June 18, 2002: US06407213 (392 worldwide citation)

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.


4
Esohe Ekinaduese Idusogie, Leonard G Presta, Michael George Mulkerrin: Polypeptide variants. Genentech, Wendy M Lee, February 27, 2001: US06194551 (344 worldwide citation)

A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, ...


5
Paul J Carter, Leonard G Presta, John B Ridgway: Method for making heteromultimeric polypeptides. Genentech, Wendy M Lee, March 24, 1998: US05731168 (236 worldwide citation)

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protube ...


6
Esohe Ekinaduese Idusogie, Leonard G Presta, Michael George Mulkerrin: Polypeptide variants. Genentech, Wendy M Lee, March 4, 2003: US06528624 (233 worldwide citation)

A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q b ...


7
Leonard G Presta, Bradley R Snedecor: Altered polypeptides with increased half-life. Genentech, Janet E Hasak, April 14, 1998: US05739277 (222 worldwide citation)

Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.


8
Leonard G Presta, Bradley R Snedecor: Altered polypeptides with increased half-life. Genentech, Walter H Dreger, February 9, 1999: US05869046 (209 worldwide citation)

Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.


9
Leonard G Presta, Bradley R Snedecor: Altered polypeptides with increased half-life. Genentech, Wendy Flehr Hohabch Test Albritton & Herbert Lee, September 19, 2000: US06121022 (193 worldwide citation)

Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.


10
Esohe Ekinaduese Idusogie, Leonard G Presta, Michael George Mulkerrin: Polypeptide variants. Genentech, Wendy M Lee, March 25, 2003: US06538124 (189 worldwide citation)

Isolated nucleic acid, vectors and host cells encoding antibody or immunoadhesin variants, as well as a process for producing the variants. The variants comprise a human IgG Fc region with amino acid substitution(s) therein, and display altered C1q binding function.